Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers



Status:Recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:9/27/2018
Start Date:September 17, 2018
End Date:April 2021
Contact:Trial Transparency email recommended (Toll free number for US & Canada)
Email:Contact-Us@sanofi.com
Phone:800-633-1610

Use our guide to learn which trials are right for you!

A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to describe the safety profile of MenACYW conjugate
vaccine and MENVEO® when administered concomitantly with routine pediatric vaccines in
healthy infants and toddlers

Approximately 16 months, which includes a safety follow-up contact at 6 months after the
final vaccination

Inclusion criteria :

- Aged ≥ 42 to ≤ 89 days on the day of the first study visit.

- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg.

- Informed consent form has been signed and dated by the parent(s) or guardian (and by
an independent witness if required by local regulations).

- Subject and parent/guardian are able to attend all scheduled visits and to comply with
all trial procedures.

- Infants who received the first dose of hepatitis B vaccine at least 28 days before the
first study visit

Exclusion criteria:

- Participation at the time of study enrollment or in the 4 weeks preceding the first
trial vaccination or planned participation during the present trial period in another
clinical trial investigating a vaccine, drug, medical device, or medical procedure.

- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned
receipt of any vaccine in the 4 weeks before and / or following any trial vaccination
except for influenza vaccination, which may be received at least 2 weeks before or 2
weeks after any study vaccination. This exception includes monovalent pandemic
influenza vaccines and multivalent influenza vaccines.

- Previous vaccination against meningococcal disease with either the trial vaccine or
another vaccine (i.e., mono- or polyvalent, PS, or conjugate meningococcal vaccine
containing serogroups A, C, Y, or W; or meningococcal B serogroup-containing vaccine).

- Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis
A, measles, mumps, rubella, varicella; and Haemophilus influenzae type b,
Streptococcus pneumoniae, and /or rotavirus infection or disease.

- Receipt of more than 1 previous dose of hepatitis B vaccine.

- Receipt of immune globulins, blood or blood-derived products since birth.

- Known or suspected congenital or acquired immunodeficiency; or receipt of
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or
long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
consecutive weeks) since birth.

- Family history of congenital or hereditary immunodeficiency until the immune
competence of the potential vaccine recipient is demonstrated.

- Individuals with blood dyscrasias, leukemia, lymphoma of any type, or other malignant
neoplasms affecting the bone marrow or lymphatic systems.

- Individuals with active tuberculosis

- History of any Neisseria meningitidis infection, confirmed either clinically,
serologically, or microbiologically.

- History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, hepatitis A,
measles, mumps, rubella, varicella, Haemophilus influenzae type b, Streptococcus
pneumoniae, and /or rotavirus infection/disease.

- At high risk for meningococcal infection during the trial (specifically, but not
limited to, subjects with persistent complement deficiency, with anatomic or
functional asplenia, or subjects traveling to countries with high endemic or epidemic
disease).

- History of intussusception.

- History of any neurologic disorders, including seizures and progressive neurologic
disorders.

- History of Guillain-Barré syndrome.

- Known systemic hypersensitivity to any of the vaccine components or to latex, or
history of a life-threatening reaction to the vaccine(s) used in the trial or to a
vaccine containing any of the same substances, including neomycin, gelatin, and yeast
.

- Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the
Investigator's opinion.

- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
contraindicating intramuscular vaccination in the Investigator's opinion

- Chronic illness that, in the opinion of the Investigator, is at a stage where it might
interfere with trial conduct or completion

- Any condition which, in the opinion of the Investigator, might interfere with the
evaluation of the study objectives.

- Moderate or severe acute illness/infection (according to Investigator judgment) on the
day of vaccination or febrile illness (temperature ≥ 38 C [≥ 100.4 F]). A prospective
subject should not be included in the study until the condition has resolved or the
febrile event has subsided.

- Identified as a natural or adopted child of the Investigator or employee with direct
involvement in the proposed study.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
We found this trial at
24
sites
?
mi
from
Downey, CA
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Bridgeton, MO
Click here to add this to my saved trials
?
mi
from
Buda, TX
Click here to add this to my saved trials
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
?
mi
from
Jonesboro, AR
Click here to add this to my saved trials
?
mi
from
Kaysville, UT
Click here to add this to my saved trials
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
?
mi
from
Orem, UT
Click here to add this to my saved trials
?
mi
from
Provo, UT
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Angelo, TX
Click here to add this to my saved trials
?
mi
from
South Jordan, UT
Click here to add this to my saved trials
?
mi
from
Syracuse, UT
Click here to add this to my saved trials
?
mi
from
Thornton, CO
Click here to add this to my saved trials
?
mi
from
Tullahoma, TN
Click here to add this to my saved trials
?
mi
from
West Covina, CA
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials